Tranexamic acid for haemostasis and beyond: does dose matter?
Abstract Tranexamic acid (TXA) is a widely used antifibrinolytic agent that has been used since the 1960’s to reduce blood loss in various conditions. TXA is a lysine analogue that competes for the lysine binding sites in plasminogen and tissue-type plasminogen activator impairing its interaction wi...
Main Authors: | Tammy Lam, Robert L. Medcalf, Geoffrey C. Cloud, Paul S. Myles, Charithani B. Keragala |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-09-01
|
Series: | Thrombosis Journal |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12959-023-00540-0 |
Similar Items
-
Postoperative Low-Dose Tranexamic Acid After Major Spine Surgery: A Matched Cohort Analysis
by: Lauren K. Dunn, et al.
Published: (2020-12-01) -
Plasmin, Immunity, and Surgical Site Infection
by: Stuart Hastings, et al.
Published: (2021-05-01) -
Fibrinolysis: A Primordial System Linked to the Immune Response
by: Robert L. Medcalf, et al.
Published: (2021-03-01) -
Novel therapeutics and emerging technology in haemostasis and thrombosis: highlights from the British society for haemostasis and thrombosis annual meeting
by: Claire S. Whyte, et al.
Published: (2023-09-01) -
Utility of Sonoclot analysis and tranexamic acid in tetralogy of Fallot patients undergoing intracardiac repair
by: Vikram Aggarwal, et al.
Published: (2012-01-01)